BioWorld

June 28, 2002

FDA Grants Corixa's Appeal; Bexxar Will Go Before ODAC

Corixa Corp. won an appeal against an FDA decision issued earlier this year that required additional clinical trials in order to market the cancer drug Bexxar. (BioWorld Today) Read More

Exact Sciences, LabCorp Enter Molecular Diagnostics Alliance

'Smart Bomb' Nanoparticle, Killer Gene, Canny Receptor Team Up To Starve Tumor Of Blood Supply

BioDelivery Raises $10.5M In IPO To Fund Delivery Technology

Other News To Note

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 10, 2026